

**beleave inc. ("beleave" or the "Company")** is a biotech company focused on the production of medical marijuana in Canada. The Company's wholly-owned subsidiary First Access Medical Inc. has applied for a license to cultivate and sell medical marijuana at its facility pursuant to the Marihuana for Medical Purposes Regulations outlined by Health Canada. The Company is actively working towards the development of patents through research with large Canadian institutions and the research and development of smoke harm reduction products.

### First Access Medical MMPR Program

- Production License (In Review Stage)
- Facility Completed (14,500 Sq. Ft.) with 100,000 Sq. Ft. Potential
- Endorsement by City of Hamilton Planning & Economic Development Department as their preferred project
- 550,000 grams of marijuana per year upon grant of license
- Low Cost Expansion Opportunity
- Unlimited free water supply
- Environmentally response use of adjacent solar energy project

### Retail (Storefronts)


- Immediate Revenue Stream
- E-commerce and retail sales avenues
- In person customer acquisition
- Brand recognition with massive marketing initiatives in place
- Vertical integration as government dictates litigation
- Competitive Advantage; Andrew Wnek's retail experience at Canadian Tire
- Competitive Advantage; Paul Evanov's marketing reach of 2.7 million radio listeners

### Proprietary Extracts

- Dedicated medical research team featuring seasoned analytical chemists
- Collaborative partnerships with Ryerson University
- Actively working towards patents on extraction techniques
- Patents should garner clinical trials on proprietary extracts
- Competitive advantage; Dr. David Naranjit's expertise in analytical techniques applied to proprietary extract formulation,

## Smoke Harm Reduction Product Development

- Development of high-end vaporizers with patented technology
- Partnerships with industry leaders for sale of vaporizers
- Ecommerce and retail sales avenues
- Integration with retail and proprietary extract platform
- Competitive Advantage; Dr. Peter S.
  Pennefather's career developing drug dosing technologies





# A Dynamic Team of Respected Industry Professionals

Roger Ferriera Ph.D., Chief Executive Officer

Bill Panagiotakopolous Chief Operating Officer

Bojan Krasic B.COMM, MIM, Chief Financial Officer

Andrew T. Wnek CA, CPA, B.COMM, MBA

Paul Evanov

Peter S. Pennefather Ph.D

David Naranjit Ph.D

Justin Kosalka MSc.

Shares Out.	14.8 million			
Share Price (Mar 1st)	C \$0.33			
Market Cap	C \$4.88			
Warrants	4.6 million			
Options	2.7 million			
Fully Diluted	22.1 million			

Research And Development Former researcher at Toronto Western Hospital / University Health Network. Head of beleave's clinical and biotech focused research and development platform

Low Cost Construction / Expansion Real Estate Developer - Career of working on government contracts

Corporate Governance and Financial Compliance Former investment banker at Stifel Nicolaus

Senior Financial Executive / Retail Expansion Former Senior VP of Finance and Admin at Canadian Tire, Former CFO at Heart and Stroke Foundation

Marketing and Advertising Executive Vice President at Evanov Radio Group, Canada's largest independent radio broadcaster. 2.7 million weekly listeners across 18 radio stations.

Dosing regulated Smoke Harm Reduction Products Professor at University of Toronto for 22 Years - Expertise in pharmaceutical sciences applied to development of tech for standardized dosing and drug delivery of cannabis based medicines

Development of Proprietary Extract Formulations Professor of Ryerson for 30 years - Expertise in analytical techniques applied to characterizing cannabinoid terpenoid profiles of beleave's strains, and advising on quality assurance practices

Development of Proprietary Extract Formulations Analytical chemist overseeing quality assurance practices

Stages of Expansion	Flowering Sq.ft.	(g)/ sq.ft.	Total Production (g)	Price per (g)	Cost per (g)	Total Net Revenue
Current	8,000	69	552,000	\$ 7.64	\$ 1.42	\$ 3,433,440
Phase 1	20,000	125	2,500,000	\$ 7.64	\$ 1.28	\$15,900,000
Phase 2	60,000	125	7,500,000	\$ 7.64	\$ 1.28	\$47,700,000
Phase 3	100,000	125	12,500,000	\$ 7.64	\$ 1.28	\$79,500,000

Contact Information – Sebastian de Kloet – 905-979-5173

C.B

